Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 20/20 | 0.62 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.57 |
| ▸ | IL6 | P05231 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1342206 | 0.94 | TLR7 (0.62) | TLR7NUDT1IL6 | |
| SCHEMBL2486310 | 0.94 | TLR7 (0.62) | TLR7NUDT1IL6 | |
| SCHEMBL1342908 | 0.93 | TLR7 (0.62) | TLR7NUDT1IL6 | |
| SCHEMBL3280954 | 0.93 | TLR7 (0.61) | TLR7NUDT1IL6 | |
| SCHEMBL1342709 | 0.93 | TLR7 (0.61) | TLR7NUDT1IL6 | |
| SCHEMBL1344514 | 0.90 | TLR7 (0.66) | TLR7IL6 | |
| SCHEMBL735762 | 0.88 | TLR7 (0.70) | TLR7IL6 | |
| SCHEMBL1345125 | 0.87 | TLR7 (0.55) | TLR7IL6 | |
| SCHEMBL1343754 | 0.87 | TLR7 (0.56) | TLR7IL6 | |
| SCHEMBL4457541 | 0.87 | TLR7 (0.56) | TLR7IL6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063051-B2 | 9-substituted-8-oxo-adenine compounds as toll-like receptor (TLR7) modulators | ASTRAZENECA AB (SE) | 2011-11-22 | — | — | US | claimed |
| EP-2139894-B1 | 9-SUBSTITUTED-8-OXO-ADENINE COMPOUNDS AS TOLL-LIKE RECEPTOR (TLR7) MODULATORS | ASTRAZENECA AB (SE) | 2011-10-26 | — | — | EP | claimed |
| US-20100087443-A1 | 9-SUBSTITUTED-8-OXO-ADENINE COMPOUNDS AS TOLL-LIKE RECEPTOR (TLR7) MODULATORS | ASTRAZENECA AB (SE) | 2010-04-08 | — | — | US | claimed |
| EP-2139894-A1 | 9-SUBSTITUTED-8-OXO-ADENINE COMPOUNDS AS TOLL-LIKE RECEPTOR (TLR7) MODULATORS | AstraZeneca AB (SE) | 2010-01-06 | — | — | EP | claimed |
| WO-2008114006-A1 | 9-SUBSTITUTED-8-OXO-ADENINE COMPOUNDS AS TOLL-LIKE RECEPTOR (TLR7) MODULATORS | ASTRAZENECA AB (SE) | 2008-09-25 | — | — | WO | claimed |
| US-8063051-B2 | 9-substituted-8-oxo-adenine compounds as toll-like receptor (TLR7) modulators | ASTRAZENECA AB (SE) | 2011-11-22 | — | — | US | disclosed |
| US-8063051-B2 | 9-substituted-8-oxo-adenine compounds as toll-like receptor (TLR7) modulators | ASTRAZENECA AB (SE) | 2011-11-22 | — | — | US | disclosed |
| US-8063051-B2 | 9-substituted-8-oxo-adenine compounds as toll-like receptor (TLR7) modulators | ASTRAZENECA AB (SE) | 2011-11-22 | — | — | US | disclosed |
| EP-2139894-B1 | 9-SUBSTITUTED-8-OXO-ADENINE COMPOUNDS AS TOLL-LIKE RECEPTOR (TLR7) MODULATORS | ASTRAZENECA AB (SE) | 2011-10-26 | — | — | EP | disclosed |
| US-20100087443-A1 | 9-SUBSTITUTED-8-OXO-ADENINE COMPOUNDS AS TOLL-LIKE RECEPTOR (TLR7) MODULATORS | ASTRAZENECA AB (SE) | 2010-04-08 | — | — | US | disclosed |
| US-20100087443-A1 | 9-SUBSTITUTED-8-OXO-ADENINE COMPOUNDS AS TOLL-LIKE RECEPTOR (TLR7) MODULATORS | ASTRAZENECA AB (SE) | 2010-04-08 | — | — | US | disclosed |
| US-20100087443-A1 | 9-SUBSTITUTED-8-OXO-ADENINE COMPOUNDS AS TOLL-LIKE RECEPTOR (TLR7) MODULATORS | ASTRAZENECA AB (SE) | 2010-04-08 | — | — | US | disclosed |
| EP-2139894-A1 | 9-SUBSTITUTED-8-OXO-ADENINE COMPOUNDS AS TOLL-LIKE RECEPTOR (TLR7) MODULATORS | AstraZeneca AB (SE) | 2010-01-06 | — | — | EP | disclosed |
| WO-2008114006-A1 | 9-SUBSTITUTED-8-OXO-ADENINE COMPOUNDS AS TOLL-LIKE RECEPTOR (TLR7) MODULATORS | ASTRAZENECA AB (SE) | 2008-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087443-A1 | 9-SUBSTITUTED-8-OXO-ADENINE COMPOUNDS AS TOLL-LIKE RECEPTOR (TLR7) MODULATORS | TLR9, TLR7, TLR1 | TLR7 2/4885NUDT1 127/4885IL6 1134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.